SG Americas Securities LLC Buys Shares of 11,374 Achieve Life Sciences, Inc. (NASDAQ:ACHV)

SG Americas Securities LLC purchased a new position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) in the third quarter, HoldingsChannel reports. The firm purchased 11,374 shares of the biopharmaceutical company’s stock, valued at approximately $54,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Virtu Financial LLC acquired a new stake in Achieve Life Sciences in the first quarter worth approximately $59,000. The Manufacturers Life Insurance Company bought a new stake in shares of Achieve Life Sciences in the 2nd quarter worth $69,000. Renaissance Technologies LLC raised its stake in shares of Achieve Life Sciences by 134.2% in the 2nd quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 14,360 shares in the last quarter. Rhumbline Advisers acquired a new stake in shares of Achieve Life Sciences in the second quarter valued at $197,000. Finally, Bank of New York Mellon Corp bought a new position in Achieve Life Sciences during the second quarter valued at about $482,000. 33.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on ACHV. Oppenheimer reiterated an “outperform” rating and issued a $11.00 price target on shares of Achieve Life Sciences in a research report on Thursday, August 15th. Raymond James started coverage on shares of Achieve Life Sciences in a research note on Friday, September 27th. They issued a “strong-buy” rating and a $20.00 price objective on the stock.

Achieve Life Sciences Stock Performance

Shares of NASDAQ ACHV opened at $4.84 on Tuesday. The stock’s fifty day simple moving average is $4.64 and its 200 day simple moving average is $4.75. The stock has a market capitalization of $166.21 million, a price-to-earnings ratio of -4.36 and a beta of 1.56. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.21. Achieve Life Sciences, Inc. has a 52-week low of $3.03 and a 52-week high of $5.98.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). During the same period in the previous year, the firm earned ($0.43) earnings per share. As a group, sell-side analysts forecast that Achieve Life Sciences, Inc. will post -1.03 earnings per share for the current fiscal year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.